Acupuncture for functional gastrointestinal disorders: A systematic review and meta‐analysis
Objectives The therapeutic effect of acupuncture treatments (AT) on functional gastrointestinal disorders (FGIDs) is contentious. A meta‐analysis was conducted to assess the efficacy and safety of acupuncture for FGIDs. Methods The Cochrane Library, EMBASE, PUBMED, Web of Science, Wanfang Database,...
Gespeichert in:
Veröffentlicht in: | Journal of gastroenterology and hepatology 2021-11, Vol.36 (11), p.3015-3026 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objectives
The therapeutic effect of acupuncture treatments (AT) on functional gastrointestinal disorders (FGIDs) is contentious. A meta‐analysis was conducted to assess the efficacy and safety of acupuncture for FGIDs.
Methods
The Cochrane Library, EMBASE, PUBMED, Web of Science, Wanfang Database, China National Knowledge Infrastructure, and VIP Database were searched through December 31, 2019 with no language restrictions. Risk ratio (RR) with 95% confidence interval (CI) was calculated to determine the improvement in symptom severity after treatment.
Results
A total of 61 randomized controlled trials (RCTs) on FGIDs were included. The pooled results illustrated the following: compared to pharmacotherapy (RR 1.13, 95% CI 1.09–1.17), placebo acupuncture (RR 1.69, 95% CI 1.37–2.08), no specific treatment (RR 1.86, 95% CI 1.31–2.62), and AT as an adjuvant intervention to other active treatments (RR 1.25, 95% CI 1.21–1.30), AT had more favorable improvements in symptom severity; sub‐group analysis results classified according to functional dyspepsia, irritable bowel syndrome, and functional constipation also supported this finding; and the incidence of adverse events was lower in AT than in other treatments (RR 0.75, 95% CI 0.56–0.99).
Conclusions
This meta‐analysis found that AT was significantly associated with relief of FGIDs symptoms; however, the evidence level was moderate or low. Further data from rigorously designed and well powered RCTs are needed to verify the effectiveness and safety of AT as a FGIDs treatment.
PROSPERO PROTOCOL NUMBER: CRD42020169508. |
---|---|
ISSN: | 0815-9319 1440-1746 1440-1746 |
DOI: | 10.1111/jgh.15645 |